Figure 2.

In female mice, LPS-induced inflammatory conditions were tempered by lumateperone. The doses used for LPS and lumateperone mirrored those of the study design for male mice. LPS (500 µg/kg subcutaneous) and lumateperone or vehicle were coinjected intraperitoneally, immediately thereafter. Samples were collected 2 h after these injections, and mRNA was analyzed by qRT-PCR or serum by multiplex. A–B, A dose–response was performed for lumateperone at 0.3, 3, and 8 mg/kg. Results show hippocampal mRNA levels of Il1b, Tnfa, Il6, and Il10 mRNA normalized to the control group (in blue) using the Dct method; n = 5–12 per group. C–D, The ability of lumateperone to normalize inflammation levels was confirmed in serum in female mice injected with a dose of lumateperone of 3 mg/kg. Protein levels from blood serum were analyzed by Multiplex MSD assay V-Plex technology and expressed in pg/ml for IL-1β, TNF-α, and IL-10, and in ng/ml for IL-6. Graphs are mean ± SEM; n = 6-8 per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA followed by Bonferroni multiple comparison test. contr, Control; Dct, δ ct; Luma, lumateperone; Tnfa, tumor necrosis factor-α; veh, vehicle.